Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Bacterial Inhibitor
GSK729 is a selective inhibitor of EchA6, a critical enzyme involved in the fatty acid biosynthesis pathway of Mycobacterium tuberculosis. By specifically targeting and inhibiting EchA6, GSK729 demonstrates significant bactericidal activity, effectively obstructing the growth of the bacterium. This compound is valuable for research applications focused on the development of new therapeutic strategies against tuberculosis and exploring the role of fatty acid synthesis in bacterial pathogenesis. -
β-lactamase Inhibitor
FPI-1602 is a β-lactamase inhibitor that enhances the efficacy of β-lactam antibiotics. It exhibits significant antimicrobial activity against pathogens such as Pseudomonas aeruginosa, Escherichia coli, and Enterobacter spp. This compound is valuable for research applications aimed at overcoming antibiotic resistance mediated by β-lactamase enzymes. -
Parasite Inhibitor
Melilotigenin C is a natural product derived from the genus Erythrina, primarily acting as a parasite inhibitor. It exhibits significant antiplasmodial activity, making it a candidate for studies focused on malaria treatment. Additionally, Melilotigenin C demonstrates antimycobacterial properties and presents potential for cytotoxicity research, contributing to the exploration of new therapeutic agents against infectious diseases. -
Bacterial Inhibitor
NBTIs-IN-4 is a potent bacterial inhibitor targeting DNA gyrase and topoisomerase IV in Gram-positive pathogens. It exhibits significant antibacterial activity while maintaining a low frequency of resistance. This compound is valuable for research applications aimed at understanding bacterial resistance mechanisms and developing new antibacterial therapies. -
Bacterial Inhibitor
BPH-1358 free base is a potent inhibitor of human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS), exhibiting IC50 values of 1.8 μM and 110 nM, respectively. This compound demonstrates significant antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of approximately 250 ng/mL. BPH-1358 free base is suitable for research applications aimed at understanding bacterial resistance mechanisms and developing novel antibacterial strategies. -
Bacterial Inhibitor
Lankacidin C 8-acetate is an antibiotic that targets bacterial pathogens through its antibacterial activity. This compound, part of the Lankacidin antibiotic group, exhibits significant inhibitory effects against specific bacterial strains. Additionally, Lankacidin C 8-acetate can react with various acyl donors to generate ester derivatives, highlighting its relevance in antibiotic synthesis and development for research applications. -
Bacterial Inhibitor
Macranthoside A is a triterpene glycoside that acts as a bacterial inhibitor. It demonstrates significant antimicrobial activity, making it a useful compound for research applications aimed at studying bacterial infections and evaluating potential therapeutic agents against microbial resistance. -
Bacterial Inhibitor
I-A09 is a bacterial inhibitor that demonstrates significant antitubercular activity against Mycobacterium tuberculosis H37Rv. This compound and its derivatives, particularly the 1,2,3-triazole-adamantylacetamide hybrids synthesized via copper-catalyzed click chemistry, display enhanced efficacy with a minimum inhibitory concentration (MIC) as low as 3.12 μg/mL. These novel analogues, particularly N-(1-adamantan-1-yl)-2-(4-(phenanthren-2-yl)-1H-1,2,3-triazol-1-yl)acetamide (5t), have applications in research focused on tuberculosis treatment and the development of new antitubercular agents. -
Bacterial Inhibitor
Antibacterial Agent 95 is a potent bacterial inhibitor with a primary target of Mycobacterium tuberculosis. Demonstrating a minimum inhibitory concentration (MIC) as low as 0.3 μM against the reference strain H37Rv, this 2-(quinoline-4-methoxy)acetamide compound effectively inhibits the growth of Mycobacterium tuberculosis in macrophage models of tuberculosis infection. Its exceptional activity makes it a valuable tool for research in antitubercular drug development. -
β-lactamase Inhibitor
Brobactam is a potent synthetic β-lactamase inhibitor designed to combat antibiotic resistance by inhibiting β-lactamase enzymes. It exhibits broad-spectrum antibacterial activity, making it valuable in the study and treatment of β-lactamase-mediated resistance in various bacterial infections. Research applications include the evaluation of combination therapies and the development of novel antibacterial agents. -
Bacterial Inhibitor
Pelagiomicin A is a phenazine antibiotic with a primary mechanism targeting bacterial cell functions. This compound demonstrates significant antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool for research in microbial resistance. Additionally, Pelagiomicin A has shown promising antitumor effects in vitro and in vivo, underscoring its potential applications in cancer research. Its structure has been elucidated through a combination of spectroscopic data and synthesis techniques, contributing to the understanding of its biological properties. -
DHPS Inhibitor
Dihydropteroate synthase-IN-1 is a potent inhibitor of dihydropteroate synthase (DHPS), primarily targeting the folate biosynthesis pathway. This compound exhibits significant antimicrobial and antifungal properties, making it valuable for research in microbial resistance and pathogenicity studies. Additionally, Dihydropteroate synthase-IN-1 has implications in diagnostics as a potential radio imaging agent, advancing the exploration of therapeutic interventions. -
β-Lactamase Inhibitor
KSP-1007 is a bicyclic boronate compound functioning as a broad-spectrum β-lactamase inhibitor. It effectively targets class A, B, C, and D β-lactamases, including serine-type and metallo-type enzymes such as NDM, VIM, and IMP, in addition to Acinetobacter baumannii OXA-type enzymes. KSP-1007 enhances the antibacterial activity of Meropenem, decreasing its minimum inhibitory concentration (MIC) against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. This reagent is suitable for research on bacterial infections and antibiotic resistance mechanisms. -
Bacterial Inhibitor
2'-Hydroxy-2-methoxychalcone acts as a bacterial inhibitor, demonstrating significant antimicrobial activity against various bacterial strains. This synthetic chalcone derivative is valuable for research in understanding bacterial resistance mechanisms and developing new antimicrobial agents. Its structural properties facilitate the exploration of structure-activity relationships in the field of medicinal chemistry. -
Bacterial Inhibitor
Chinfloxacin is a bacterial inhibitor that exerts antibacterial activity against a range of clinical isolates in vitro. Demonstrating a concentration-dependent bactericidal effect, Chinfloxacin shares antibacterial efficacy comparable to that of moxifloxacin. This compound is suitable for research applications focused on bacterial pathogenicity and the development of new antimicrobial agents. -
Bacterial Inhibitor
Phenethicillin potassium is a β-lactam antibiotic that targets bacterial cell wall synthesis by inhibiting penicillin-binding proteins. It demonstrates significant antibacterial activity against a range of Gram-positive bacteria, making it valuable in research applications focused on antimicrobial resistance and the mechanistic understanding of bacterial susceptibility. Its characteristic action profile facilitates studies in microbiology and pharmacology, providing insights into antibiotic efficacy and resistance mechanisms. -
Bacterial Inhibitor
Hikizimycin is a potent antibacterial agent that targets bacterial cell growth and division. This natural product exhibits significant antibacterial activity, making it a valuable tool for research focused on bacterial infections and their treatment. Its unique mechanism of action offers insights into new therapeutic strategies for combating antibiotic resistance. -
Bacterial Inhibitor
Antibacterial Agent 28 is a bacterial inhibitor with a mechanism targeting the growth and proliferation of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA). It exhibits antimicrobial activity with minimum inhibitory concentrations (MICs) ranging from 0.5 to 2 μg/mL. This reagent holds promise for research applications aimed at developing new treatments against resistant bacterial infections. -
MabA (FabG1) Inhibitor
FabG1-IN-1 is a selective inhibitor of MabA (FabG1), exhibiting an IC50 of 38 µM. This compound effectively impedes the enzymatic activity of FabG1, playing a crucial role in fatty acid biosynthesis. FabG1-IN-1 is applicable in research focusing on metabolic pathways and the development of antifungal therapies targeting lipid synthesis. -
β-Lactamase Inhibitor
Ledaborbactam etzadroxil is an orally active inhibitor of Ambler class A, C, and D β-lactamase enzymes. It is designed to provide enhanced protection for β-lactam antibiotics from hydrolysis by these enzymes, thereby improving their efficacy. This compound is particularly relevant in research applications focused on combating antibiotic resistance and expanding the therapeutic options for bacterial infections. -
Bacterial Inhibitor
β-L-Gulopyranosyl-caldarchaetidyl-glycerol (GuCGp) is a polar lipid compound targeting bacterial membranes. Its role in the lipid composition of thermoacidophilic bacteria is crucial for understanding bacterial adaptation to varying environmental conditions. This compound is valuable for research applications focused on microbial physiology and membrane biochemistry. -
Bacterial Inhibitor
Ceratotoxin B is an antibacterial peptide derived from the sexually mature females of Ceratitis capitata. It exhibits lytic and antibacterial activity, making it a valuable research tool for studying bacterial inhibition and antimicrobial mechanisms. This peptide can be utilized in studies aimed at understanding bacterial resistance and the development of novel antibacterial agents. -
Bacterial Inhibitor
TP0586352 is a potent LpxC inhibitor specifically designed to target bacterial pathogens, including carbapenem-resistant Klebsiella pneumoniae. This compound exhibits significant antibacterial activity while maintaining a favorable safety profile, as it does not pose cardiovascular risks. Additionally, TP0586352 features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions for further chemical modifications. -
Bacterial Inhibitor
Propioxatin B is a tricyclic sesquiterpenoid compound that acts as a bacterial inhibitor. This compound demonstrates significant anti-tuberculosis activity, exhibiting effectiveness against various drug-resistant Mycobacterium tuberculosis strains. In silico docking studies indicate that Propioxatin B binds with bacterial DNA gyrase, suggesting a targeted mechanism of action and potential safety in in vivo applications. -
Bacterial Inhibitor
Drimentine A is a terpenylated diketopiperazine that acts as a bacterial inhibitor, originally isolated from Actinomycete bacteria. It exhibits significant antibacterial activity, making it a valuable tool in microbiological studies. This compound is primarily utilized in research involving bacterial pathogenesis and the development of antimicrobial agents. Unlike its analogs Drimentine B and C, Drimentine A does not possess anticancer activity. -
β-lactamase Inhibitor
β-Lactamase-IN-8 is a potent β-lactamase inhibitor with a broad-spectrum profile, utilizing a cyclic boronate structure to enhance oral bioavailability. It effectively inhibits various β-lactamases, making it a valuable tool for studying antibacterial resistance mechanisms and developing new therapeutic strategies against resistant bacterial strains. Researchers can utilize β-Lactamase-IN-8 for investigating the efficacy of β-lactam antibiotics in microbial infections. -
Metallo-β-lactamase Inhibitor
β-Lactamase-IN-7 is a potent inhibitor of VIM-type metallo-β-lactamases, exhibiting inhibition constants (Ki) of 1.26 μM and 0.54 μM for VIM-1 and VIM-4, respectively. This compound demonstrates effective inhibition against Klebsiella pneumoniae, making it valuable for studies focused on antibiotic resistance and the development of novel therapeutic strategies against resistant bacterial infections. Its role in characterizing metallo-β-lactamase activity positions it as an important tool in chemical biology research. -
CCR Inhibitor
CCR6 Inhibitor 1 is a highly selective inhibitor of the CCR6 receptor, demonstrating IC50 values of 0.45 nM for monkey CCR6 and 6 nM for human CCR6, while exhibiting minimal activity against human CCR1 and CCR7. This inhibitor effectively prevents ERK phosphorylation, making it a valuable tool in the study of signaling pathways. CCR6 Inhibitor 1 is employed in research focused on autoimmune diseases and cancer, facilitating insights into therapeutic strategies targeting CCR6-related pathways. -
CCR4 Inhibitor
Zelnecirnon is an orally active CCR4 inhibitor that effectively blocks the recruitment of Th2 inflammatory immune cells to inflamed tissues. This compound exhibits potent anti-inflammatory activity, making it valuable in researching allergic inflammation associated with conditions such as atopic dermatitis and asthma. Zelnecirnon serves as a critical tool for understanding and developing therapeutic strategies in inflammatory diseases. -
CCR Inhibitor
Ilacirnon is a potent CCR2 antagonist that specifically targets the C-C chemokine receptor type 2 (CCR2). This compound exhibits significant inhibitory activity, making it valuable in research focused on inflammatory diseases and immune response modulation. Ilacirnon can be utilized in studies exploring the role of CCR2 in various pathophysiological conditions, including atherosclerosis and chronic kidney disease. -
CCR3 Inhibitor
ALK4290 is a potent, orally active inhibitor of CCR3, exhibiting a Ki of 3.2 nM for human CCR3. Its biological activity positions ALK4290 as a valuable tool for research into neovascular age-related macular degeneration and Parkinsonism. This compound may help elucidate the role of CCR3 in these diseases, facilitating the development of targeted therapeutic strategies. -
hCCR2 Inhibitor
JNJ-41443532 is a selective antagonist of the human CCR2 receptor, exhibiting an IC50 of 37 nM for binding and demonstrating potent functional antagonism with an IC50 of 30 nM in chemotaxis assays. This compound shows a Ki value of 9.6 µM for murine CCR2 binding. JNJ-41443532 is suitable for research into inflammatory diseases and related inflammatory pathways. -
CCR3 Inhibitor
ALK4290 dihydrochloride is a potent inhibitor of the CCR3 receptor, exhibiting a Ki value of 3.2 nM for human CCR3. This compound demonstrates significant potential for modulating immune responses, making it a valuable tool in the study of neovascular age-related macular degeneration and Parkinson's disease. Researchers can utilize ALK4290 to investigate its effects on CCR3-related signaling pathways and its implications in various pathological conditions. -
CCR2 Inhibitor
ECL1i is an allosteric inhibitor targeting the CCR2 receptor. It selectively disrupts CCL2/CCR2-mediated chemotaxis, thereby impeding the recruitment of CCR2-positive cells. ECL1i has demonstrated efficacy in attenuating disease progression in models of experimental autoimmune encephalomyelitis, making it a valuable tool for studying autoimmune disease mechanisms and potential therapeutic interventions. -
CCR1 Inhibitor
BX-513 is a potent and selective antagonist of the CCR1 receptor. It effectively inhibits the binding of radiolabeled MIP-1α and RANTES to CCR1, with inhibition constants (Ki) of 40 nM and 60 nM, respectively. BX-513 demonstrates the ability to suppress MIP-1α-induced extracellular acidification, as well as MIP-1α- and RANTES-induced intracellular calcium mobilization and peripheral blood mononuclear cell migration. This compound is applicable in research focusing on autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. -
CCR2 Inhibitor-DOTA Conjugate
DOTA-ECL1i is a CCR2 inhibitor conjugated with DOTA, designed for use in positron emission tomography (PET) imaging. When radiolabeled with 68Ga, DOTA-ECL1i provides a specific PET tracer that targets CCR2 expression in various pathological conditions. This compound is applicable in research focused on pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, and cancers of the head, neck, and pancreas. -
CCR5/CXCR3 Inhibitor
CCR5/CXCR3-IN-1 is a potent inhibitor of the chemokine receptors CXCR3 and CCR5. This compound effectively suppresses the chemotaxis of transformed cells expressing CCR5 and CXCR3, while exhibiting no inhibitory effect on CXCR4-expressing transfected cells. CCR5/CXCR3-IN-1 is valuable for research into chronic arthritic rheumatism and other conditions where modulation of these receptors is crucial. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-84 (NSC-615985) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. By targeting the reverse transcriptase enzyme, UC-84 effectively disrupts viral replication, making it a valuable compound for HIV research. Its application extends to studies focused on the mechanisms of viral resistance and the development of novel therapeutic strategies against HIV. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics.
